Form 144 - Report of proposed sale of securities:
SEC Accession No. 0000950170-25-031097
Filing Date
2025-03-03
Accepted
2025-03-03 18:00:02
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html 144  
1 primary_doc.xml 144 3182
  Complete submission text file 0000950170-25-031097.txt   4657
Mailing Address 500 NORTH BEACON STREET, 4TH FLOOR WATERTOWN MA 02472
Business Address 500 NORTH BEACON STREET, 4TH FLOOR WATERTOWN MA 02472 857-285-5314
Kymera Therapeutics, Inc. (Subject) CIK: 0001815442 (see all company filings)

EIN.: 812992166 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 144 | Act: 33 | File No.: 001-39460 | Film No.: 25700405
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address C/O KYMERA THERAPEUTICS, INC. 200 ARSENAL YARDS, SUITE 230 WATERTOWN MA 02472
Business Address
Gollob Jared (Reporting) CIK: 0001821198 (see all company filings)

Type: 144